Rosacea

Positive results reported from COL-3 trial for rosacea

Published in Immunotherapy Weekly, May 18th, 2005

CollaGenex Pharmaceuticals, Inc., (CGPI) announced the results of a double-blinded, placebo-controlled, phase II clinical study designed to evaluate the safety and efficacy of COL-3 for the treatment of rosacea.

This multicenter study was conducted by Guy Webster, MD, Thomas Jefferson University, Philadelphia, Pennsylvania; Robert Skidmore, MD, Gainesville, Florida; and Anna Duarte, MD, Children's Skin Center, Miami, Florida.

This was a small, phase II, proof-of-principle study that enrolled 13 patients who received either COL-3 or placebo for 28 days. Patients were evaluated at baseline and at days 14, 28, and 42. Inflammatory lesion counts and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly

Source: Immunotherapy Weekly (2005-05-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry